Vitamin D3 for Life

Live Enlightened

Article

Pathophysiological consequences of altered enzyme activity: Study Summary

Previous related pagePathophysiological consequences of altered enzyme activity: Full Study SummaryNext related pagePhysiological regulation of clearance and feedback: Full Evidence Review
Study at a glance

How can vitamin D processing go wrong?

This page summarises evidence about disorders of vitamin D processing. It combines human genetic disorders, animal experiments and laboratory cell studies rather than reporting one clinical trial. The central distinction is between failing to make enough active vitamin D, failing to remove vitamin D compounds normally, and making too much active vitamin D outside the kidneys.

What happens when vitamin D activation or removal fails?

Enzymes are proteins that help chemical reactions occur. CYP27B1 helps make calcitriol, the active vitamin D hormone. Severe loss of this enzyme can cause rickets, in which growing bones do not harden properly, even when an earlier form of vitamin D is available. CYP24A1 helps process vitamin D compounds for removal. Its failure can cause high calcium in blood or urine and kidney complications. The severity varies between people.

How do hormones and disease affect the active vitamin D supply?

Parathyroid hormone usually favours production of active vitamin D. FGF23 and active vitamin D itself tend to reduce production and promote further processing. Kidney disease can reduce activation without an inherited enzyme defect. In certain diseases, including sarcoidosis and tuberculosis, immune cells outside the kidneys can produce enough active vitamin D to contribute to high blood calcium.

What do these vitamin D disorders not show about other people?

Some processes remain uncertain. These include conflicting effects of the hormone calcitonin and incomplete explanations of how the body detects calcium and phosphate levels. Results from animal or cell experiments do not directly show how large the effects are in people. The review does not show that every difference in a gene causes severe disease, that enzyme faults commonly explain vague symptoms, or that ordinary activity outside the kidneys supplies most active vitamin D in the blood.

Read the full article below ↓

Young and colleagues review what happens when vitamin D activation and inactivation move too far in either direction. The clearest disease mechanisms are deliberately different: CYP27B1 loss prevents adequate calcitriol formation, CYP24A1 loss prevents normal vitamin D metabolite inactivation, and dysregulated extra-renal CYP27B1 can produce excessive calcitriol in granulomatous disease. The review also explains how those disorders sit within normal renal feedback involving PTH, calcitriol, FGF23, calcitonin, calcium and phosphate.

What is the normal physiological setting?

The kidney is the principal regulated source of circulating calcitriol. In proximal tubular cells, 25(OH)D is delivered to mitochondrial CYP27B1 for 1α-hydroxylation, while CYP24A1 promotes further metabolism of 25(OH)D and calcitriol.

The two enzymes are regulated reciprocally within the broader Vitamin D Enzyme Pathways (CYP27B1 / CYP24A1) system. PTH generally favours calcitriol availability; calcitriol feeds back to suppress CYP27B1 and induce CYP24A1; and FGF23 shifts the balance toward lower active-hormone production and greater catabolic pressure.

How does the review build the disease mechanisms?

This is a narrative review rather than one clinical trial. It links human genetic disorders with animal physiology, promoter experiments and cell-signalling studies. That mixture is useful because different evidence types answer different questions: human mutations show that loss of a particular enzyme can cause disease, animal models quantify regulatory responses that cannot easily be manipulated in people, and cellular experiments help identify signalling pathways. Numerical effects therefore retain the boundaries of the model in which they were measured.

What happens when CYP27B1 is lost?

Pathogenic CYP27B1 loss-of-function causes vitamin-D-dependent rickets type 1A. The biochemical defect lies after 25(OH)D formation, so precursor can be present while calcitriol remains inadequate.

The phenotype includes hypocalcaemia, hypophosphataemia, secondary hyperparathyroidism and rickets. Calcitriol treatment can bypass the missing enzyme step, which is strong evidence that the disease is an activation defect rather than simply a shortage of vitamin D precursor. Chronic kidney disease can also reduce calcitriol production, but through loss of functioning renal tissue and altered endocrine regulation rather than a primary CYP27B1 mutation. The distinction matters because similar low-calcitriol physiology can arise from different upstream causes.

What happens when CYP24A1 is lost?

CYP24A1 loss creates the opposite problem. Vitamin D metabolites are not inactivated normally, increasing exposure and creating a tendency toward hypercalcaemia and hypercalciuria. Recognised phenotypes include idiopathic infantile hypercalcaemia and later nephrolithiasis or nephrocalcinosis.

Clinical severity varies, so a CYP24A1 variant should not automatically be equated with the most severe infantile presentation. The robust mechanistic point is impaired degradation, not one fixed disease severity.

How can extra-renal CYP27B1 cause hypercalcaemia?

Activated macrophages in granulomatous disease can express CYP27B1 and generate calcitriol outside the kidney. In conditions such as sarcoidosis and tuberculosis, this local enzyme capacity can become large enough to contribute to systemic hypercalcaemia.

This is excessive production rather than failed clearance. It also should not be projected onto ordinary extra-renal physiology, where CYP27B1 often supports local signalling without dominating circulating calcitriol.

What do PTH and FGF23 show about the enzyme balance?

PTH stimulates CYP27B1 and also weakens the catabolic side. The review reports an approximately fourfold reduction in CYP24A1 mRNA half-life in the presence of PTH. This allows one hormone to favour active vitamin D through both increased synthesis and reduced catabolic transcript persistence.

FGF23 works in the opposite direction. In FGF23-null mice, renal CYP27B1 promoter activity was about threefold higher, while renal Cyp24a1 mRNA was about 63% lower than in wild type. These results support reciprocal control of activation and catabolism.

Which parts of the regulatory model remain uncertain?

Calcitonin generally stimulates CYP27B1, but its effect on CYP24A1 differs between experimental systems. In calcitonin-receptor-transfected HEK-293 cells, PKA or PKC inhibition reduced the induced CYP24A1 response by about 60%, while animal studies described a different direction of effect. The discrepancy remains unresolved.

Low phosphate can increase calcitriol production by roughly threefold, but the sensing pathway is not fully mapped and can depend on pituitary influences in experimental models. Calcium can also suppress Cyp27b1 in controlled animal experiments, although the complete signalling route remains incomplete.

What should a reader take from the disease evidence?

CYP27B1 failure, CYP24A1 failure and pathological extra-renal activation are not interchangeable forms of “enzyme imbalance.” They are distinct mechanisms that alter the same mineral-homeostasis network from different directions.

The review supports these defined disorders and regulatory pathways. It does not show that clinically important CYP27B1/CYP24A1 dysfunction is a common explanation for nonspecific symptoms, and it does not imply that every genetic variant produces severe disease. The useful clinical lesson is mechanistic: before interpreting an abnormal vitamin D pattern, ask whether the dominant problem is impaired activation, impaired degradation, excessive extra-renal production or a broader renal/endocrine disturbance.

Primary source and further reading

Young K, Beggs MR, Grimbly C, Alexander RT. Regulation of 1 and 24 hydroxylation of vitamin D metabolites in the proximal tubule. Experimental Biology and Medicine (Maywood). 2022;247(13):1103 to 1111. PMID 35482362; PMCID PMC9335508; DOI 10.1177/15353702221091982.

Read the full Young et al. review. The Full Evidence Review develops the regulatory experiments and disease boundaries in greater depth.

Related reading

Original sources

Source

Read the full Young et al. review

Read the full Young et al.

Publication details

Read the full Young et al. review. The Full Evidence Review develops the regulatory experiments and disease boundaries in greater depth.

Read more →